Human Galectin-3-binding protein(LGALS3BP) ELISA kit

Instructions
Code CSB-EL012888HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name lectin, galactoside-binding, soluble, 3 binding protein
Alternative Names 90K ELISA Kit; 90K MAC 2 BP ELISA Kit; Basement membrane autoantigen p105 ELISA Kit; BTBD17B ELISA Kit; Galectin 3 binding protein ELISA Kit; Galectin-3-binding protein ELISA Kit; L3 antigen ELISA Kit; Lectin galactoside binding soluble 3 binding protein ELISA Kit; Lectin galactoside-binding soluble 3-binding protein ELISA Kit; LG3BP_HUMAN ELISA Kit; LGALS3BP ELISA Kit; M2BP ELISA Kit; Mac 2 binding protein ELISA Kit; Mac 2 BP ELISA Kit; Mac-2 BP ELISA Kit; Mac-2-binding protein ELISA Kit; Mac2 BP ELISA Kit; MAC2BP ELISA Kit; Serum protein 90K ELISA Kit; TANGO10B ELISA Kit; Transport and golgi organization 10 homolog B ELISA Kit; Tumor associated antigen 90K ELISA Kit; Tumor-associated antigen 90K ELISA Kit
Abbreviation LGALS3BP
Uniprot No. Q08380
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 1.56 ng/mL-100 ng/mL
Sensitivity 0.39 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human LGALS3BP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:20 Average % 91  
Range % 84-98  
1:40 Average % 90  
Range % 85-95  
1:60 Average % 97  
Range % 92-102  
1:160 Average % 102  
Range % 96-108  
Recovery
The recovery of human LGALS3BP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 100 95-106  
EDTA plasma (n=4) 90 85-95  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
100 2.620 2.645 2.633 2.541  
50 2.265 2.366 2.316 2.224  
25 1.628 1.673 1.651 1.559  
12.5 0.921 0.855 0.888 0.796  
6.25 0.571 0.589 0.580 0.488  
3.12 0.333 0.355 0.344 0.252  
1.56 0.190 0.188 0.189 0.097  
0 0.093 0.090 0.092    
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Promotes integrin-mediated cell adhesion. May stimulate host defense against viruses and tumor cells.
Gene References into Functions
  1. Serum M2BP might contribute to the inflammatory process in systemic lupus erythematosus. PMID: 29233037
  2. M2BP inhibits both HIV-1 Env processing and virion production.M2BP traps HIV-1 Gag to vimentin filaments to inhibit the transportation of HIV-1 Gag to the plasma membrane. PMID: 27604950
  3. Results showed that 90K destabilizes E-cadherin and affects cell adhesion and invasion in subconfluent cancer cells via dissociation of the E-cadherin-p120-catenin complex, suggesting that 90K drives less confluent tumor cells into the early steps of cancer metastasis. PMID: 29207493
  4. Low LGALS3BP expression is associated with HIV infections. PMID: 29743357
  5. Data suggest that serum levels of RBP4 and LGAL3BP are up-regulated after menopause when complicated by NAFLD (non-alcoholic fatty liver disease); RBP4 and LGAL3BP may serve as biomarkers of NAFLD in postmenopausal women. (RBP4 = retinol binding protein 4; LGAL3BP = galectin-3 binding protein) PMID: 29679552
  6. Elevated plasma M2BP levels might be predictive of unstable plaque and were associated independently with poor cardiovascular outcomes in patients with acute coronary syndromes. PMID: 28731888
  7. Serum Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. PMID: 28811008
  8. A higher pre-treatment WFA+-M2BP level was associated with an increased risk of HCC development in patients with undetectable HBV DNA under NA therapy. PMID: 28537900
  9. the combination of 17-AAG and PI3K/Akt inhibitor would effectively suppress acquired resistance to 17-AAG. In conclusion, targeting of LGALS3BP-mediated-specific survival signaling pathway in resistant cells may provide a novel therapeutic model for the cancer therapy. PMID: 28336809
  10. serum M2BP may reflect silent atherosclerosis in apparently healthy subjects PMID: 27344370
  11. the serum M2BP-adiponectin complex is elevated in men with coronary artery disease PMID: 27588936
  12. WFA + -M2BP from hepatic stellate cells induces Mac-2 expression in Kupffer cells, which in turn activates hepatic stellate cells to be fi brogenic. PMID: 28008658
  13. The Mac-2BP may have a role in regulating the extracellular spreading and storage of the Wnts, thereby modulating their bioavailability and stability. PMID: 28756229
  14. Our present results highlight the action of 90K on promoting degradation of mutant beta-catenin lacking the phosphorylation sites in the N-terminus. PMID: 27668402
  15. Serum M2BP can be a useful biomarker for the diagnosis of pancreatic ductal adenocarcinoma and the prediction of disease progression since it potentially reflects altered pro-oncologic glycosylation enzymes PMID: 27665173
  16. In this study, we addressed this question by analysing sLex expression together with two glycoproteins (BST-2 and LGALS3BP).Concomitant high expression of BST-2 with sLex defined a sub-group of patients with ER-negative tumours displaying higher risks of liver and brain metastasis and a 3-fold decreased survival rate PMID: 27176937
  17. Results showed that in acute febrile phase, galectin-9 and galectin-3BP were induced in dengue patients compared to healthy controls suggesting that both molecules might be important inflammatory mediators in acute dengue virus infection. PMID: 27240351
  18. 90K/Mac-2BP correlated with the size of colorectal cancer. PMID: 26448934
  19. Results provide direct evidence for the involvement of CALU and LGALS3BP as potential negative regulators in the virus-triggered induction of the typeI interferons. PMID: 26124285
  20. These results provide evidence that low expression of LGALS3BP participates in malignant progression of colorectal cancer. PMID: 26219351
  21. Post-Tx WFA+-M2BP (> 2.0 COI) is associated with the risk for development of HCC among patients with SVR. The WFA+-M2BP values could be a new predictor for HCC after SVR. PMID: 26070204
  22. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis PMID: 23775887
  23. findings may help clarify the molecular mechanism of the tumor-suppressive effect through down-regulation of LGALS3BP by miR-596 in Oral Squamous Cell Carcinoma PMID: 26502662
  24. Studied levels of galectin-3 binding protein in milk from 247 HIV-infected Zambian mothers. Levels were higher in those mothers who transmitted HIV through breast-feeding. PMID: 23899964
  25. LGALS3BP-mediated integrin activation results into signal transmission via Akt, JNK and the Ras cascade via the Raf-ERK axis while p38 activity is kept at baseline levels PMID: 24362527
  26. Gal-3BP levels in patients with haemorrhagic fever with renal syndrome correlated with increased complement activation and with clinical variables reflecting the severity of acute hantavirus infection. PMID: 25013204
  27. These findings suggest a novel immunoinhibitory function for LGALS3BP that might be important for immune evasion of tumor cells during cancer progression. PMID: 25320078
  28. Thus, 90K constitutes a novel antiviral factor that reduces the particle infectivity of HIV-1, involving interference with the maturation and incorporation of HIV-1 Env molecules into virions. PMID: 24156545
  29. LGALS3BP is enriched in human ovarian carcinoma exosomes. PMID: 24302979
  30. Recombinant 90K showed an apparent molecular weight of approximately 78kDa which was much smaller than that ( approximately 97kDa) of the natural 90K. It is suggested that recombinant 90K has small N-glycans with about half the molecular weight of N-glycans of natural 90K. PMID: 23830458
  31. The expression of serum Mac-2 binding protein is a potential therapeutic target and biomarker for lung cancer. PMID: 23184915
  32. LGALS3BP suppresses assembly of centriolar substructures. PMID: 23443559
  33. LGALS3BP induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. PMID: 22864925
  34. MIR596 is frequently observed in oral squamous cell carcinoma and regulates expression of LGAL3BP. PMID: 23233740
  35. breast cancer cells express Mac-2BP as a novel E-selectin ligand, potentially revealing a new prognostic and therapeutic target for breast cancer PMID: 22970241
  36. Single nucleotide polymorphism (SNP) of LGALS3BP gene (found in NCBI) database are not characteristic for papillary thyroid cancer, follicular adenomas and nodular goiter PMID: 17091456
  37. results show that NF-kappaB regulated the expression of G3BP and that G3BP increased the adhesion of T47D breast cancer cells to fibronectin PMID: 22447108
  38. Adeno-associated virus type 6 interacts with G3BP in human and dog sera but not in macaque serum. PMID: 22496229
  39. There is no difference in Gal-3 expression in peripheral blood lymphocytes in patients with papillary thyroid cancer PMID: 17091455
  40. LGALS3BP gene was expressed by neuroblatoma cell lines and patients' neuroblasts PMID: 21660451
  41. serum changes of three glycoproteins, galectin-3 binding protein, insulin-like growth factor binding protein 3, and thrombospondin 1, was associated with the development of hepatocellular carcinoma PMID: 21474793
  42. Mac-2BP was detected as a predominant DC-SIGN ligand expressed on some primary colorectal cancer tissues PMID: 21515679
  43. These results suggest that galectin-3 binding protein may be a potential therapeutic target for treatment of, at least, colon cancer patients with high expression of galectin-3 binding protein. PMID: 21094132
  44. Serum Mac-2BP does not appear to originate in the prostate and it is unlikely that Mac-2BP can be used for the differential diagnosis of prostate cancer versus benign prostatic hyperplasia. PMID: 20583127
  45. Initial assessment showed that serum Mac-2BP is significantly elevated in patients with NET (neuroendocrine tumors) and is expressed by the majority of NET tissues. PMID: 20019050
  46. structural and functional properties of M2BP PMID: 11867635
  47. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. PMID: 11980646
  48. REVIEW: role in tumor progression and metastasis PMID: 14758079
  49. 90K plays an important role in the maintenance of an appropriate level of immune response. PMID: 15231701
  50. Elevated Mac-2 binding protein is associated with distant metastasis and higher tumor stage in gastric cancer PMID: 17131321

Show More

Hide All

Subcellular Location Secreted, Secreted, extracellular space, extracellular matrix
Tissue Specificity Ubiquitous. Detected in body fluids such as semen, milk, serum, tears, saliva and urine. Expressed by keratinocytes and fibroblasts.
Database Links

HGNC: 6564

OMIM: 600626

KEGG: hsa:3959

STRING: 9606.ENSP00000262776

UniGene: Hs.514535

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1